The lead candidate azer-cel (PBCAR0191) is in a phase 1/2a clinical trial as a potential first-in-class cell therapy for patients with CD19 + B cell acute ... the integrated structure of its ...

The CAR structure has two main parts — an extracellular ... and are engineered to target the transmembrane antigen CD19 on B cells. Studies and clinical trials have reported that axicabtagene ...

Axi-cel, tisa-cel, and brexu-cel were found comparable to other cellular therapy experiences for patients with B-cell ...

B-cell acute lymphoblastic leukemia (B-ALL) is a life-threatening and highly aggressive form of blood cancer. It is the most ...

The option, which was part of a broader deal, gave BioNTech a chance to co-develop the cell therapy in return for an upfront fee and milestones. Building on its autologous CD19 CAR-T cell therapy ...

and structure and negotiate terms, which meet their objectives. About EB103 EB103, a T-cell therapy, also referred to as Estrella’s “CD19-Redirected ARTEMIS ® T-Cell Therapy,” utilizes ...